Pertti J. Neuvonen

34.9k citations
506 papers · 26.6k indexed · 3 hit papers · h-index 84
Topics
Pharmacogenetics and Drug Metabolism (162 papers)Pharmacological Effects and Toxicity Studies (106 papers)Drug Transport and Resistance Mechanisms (101 papers)
Partner nations
FinlandGermanySweden

In The Last Decade

Pertti J. Neuvonen

504 papers receiving 25.2k citations

Hit Papers

Drug interactions with lipid-lowering drugs: Mechanisms a...2003202620102018200620032011200400600

Peers

Pertti J. Neuvonen
Comparison fields: 5 of 172
  • Pharmacology 10.9k
  • Oncology 8.1k
  • Pediatrics, Perinatology and Child Health 5.7k
  • Surgery 4.6k
  • Pharmacology 4.1k
Replace Michel Eichelbaum with:
Michel Eichelbaum Germany
Alastair J.J. Wood United States
Kenneth E. Thummel United States
Leslie Z. Benet United States
Magnus Ingelman‐Sundberg Sweden
Janne T. Backman Finland
Paul B. Watkins United States
Ulrich M. Zanger Germany
Amin Rostami‐Hodjegan United Kingdom
J. Steven Leeder United States
Pertti J. Neuvonen relative to Michel Eichelbaum Germany Michel Eichelbaum's profile →
Citations per field
00.5×
Michel Eichelbaum · 1×
Citations per year

Countries citing papers authored by Pertti J. Neuvonen

Since Specialization
Citations

This map shows the geographic impact of Pertti J. Neuvonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pertti J. Neuvonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pertti J. Neuvonen more than expected).

Fields of papers citing papers by Pertti J. Neuvonen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pertti J. Neuvonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pertti J. Neuvonen. The network helps show where Pertti J. Neuvonen may publish in the future.

Co-authorship network of co-authors of Pertti J. Neuvonen

This figure shows the co-authorship network connecting the top 25 collaborators of Pertti J. Neuvonen. A scholar is included among the top collaborators of Pertti J. Neuvonen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pertti J. Neuvonen. Pertti J. Neuvonen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 21
2 42
3 75
4 2
5 32
6 61
7 49
8 22
9 15
10 17
11 28
12 12
13 26
14 83
15 62
16 35
17 2
18
Antihypertensive effect of trimepranol, a new beta-blocking agent.
2
19 27
20 33

About Pertti J. Neuvonen

Pertti J. Neuvonen is a scholar working on Pharmacology, Anesthesiology and Pain Medicine and Pharmacology, having authored 506 papers that have together received 26.6k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (162 papers), Pharmacological Effects and Toxicity Studies (106 papers) and Drug Transport and Resistance Mechanisms (101 papers). The work is most often cited by research in Pharmacology (10.9k citations), Anesthesiology and Pain Medicine (1.7k citations) and Oncology (8.1k citations). Pertti J. Neuvonen has collaborated with scholars based in Finland, Germany and Sweden. Frequent co-authors include Janne T. Backman, Mikko Niemi, Klaus T. Olkkola, Kari T. Kivistö, Mikko Neuvonen, Marja K. Pasanen, Jari J. Lilja, Jouko Laitila, Kari T. Kivistö and Teemu Kantola. Their work appears in journals such as The Lancet, Circulation and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026